Skip to main content
رجوع
Watch Compare

PROVECTUS BIOPHARMACEUTICALS, INC.

جودة البيانات: 100%
PVCT
OTC Manufacturing Chemicals
KWD 0.06
▲ KWD 0.00 (1.79%)
القيمة السوقية: 23.96 M
السعر
KWD 0.06
القيمة السوقية
23.96 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Negative free cash flow of -3.33 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-45.54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROICN/A
Net Margin-1615.81%
Op. Margin-1575.32%

الأمان

Debt / Equity
N/A
Current Ratio0.04
Interest Coverage-991.90

التقييم

PE (TTM)
-4.41
أقل من متوسط القطاع (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1385 نظير)
المقياس السهم وسيط القطاع
P/E -4.4 -1.5
P/B — 1.6
ROE % — -54.0
Net Margin % -1615.8 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

لا تتوفر تقديرات مستقبلية

مفاجآت الأرباح

آخر 4 أرباع
الربع EPS المقدر EPS الفعلي المفاجأة
Q42012 -KWD 0.03 -KWD 0.02 +33.3%
Q32012 -KWD 0.03 -KWD 0.02 +40.0%
Q22012 -KWD 0.03 -KWD 0.03 +10.0%
Q12012 -KWD 0.04 -KWD 0.04 -14.3%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -45.54% Revenue Growth (3Y) -22.37%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 336,108.0 Net Income (TTM) -5.43 M
ROE N/A ROA -950.87%
Gross Margin N/A Operating Margin -1575.32%
Net Margin -1615.81% Free Cash Flow (TTM) -3.33 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.04
Interest Coverage -991.90 Asset Turnover 0.59
Working Capital -6.19 M Tangible Book Value -6.15 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4.41 Forward P/E N/A
P/B Ratio N/A P/S Ratio 71.27
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -13.88%
Market Cap 23.96 M Enterprise Value 23.88 M
Per Share
EPS (Diluted TTM) -0.01 Revenue / Share 0.00
FCF / Share -0.01 OCF / Share -0.01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 61.24%
SBC-Adj. FCF -4.28 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 336,108.0 617,140.0 557,710.0 989,042.0 —
Net Income -5.43 M -4.73 M -3.10 M -3.55 M -5.54 M
EPS (Diluted) -0.01 -0.01 -0.01 — —
Gross Profit — — — — —
Operating Income -5.29 M -4.53 M -2.90 M -3.43 M -4.67 M
EBITDA — — — — —
R&D Expenses 1.90 M 2.00 M 1.75 M 2.39 M 2.61 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 5,338.0 13,591.0 5,650.0 -163,691.0 961,702.0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 697,502.0 1.01 M 1.45 M 2.04 M 3.51 M
Total Liabilities 7.00 M 6.98 M 9.04 M 8.27 M 7.70 M
Shareholders' Equity -6.30 M -5.96 M -7.59 M -6.23 M -4.19 M
Total Debt — — — — —
Cash & Equivalents 251,291.0 307,442.0 76,576.0 21,605.0 682,984.0
Current Assets 567,874.0 976,772.0 1.36 M 1.90 M 3.44 M
Current Liabilities 6.90 M 6.98 M 9.02 M 8.19 M 7.70 M